

pEF1α-AcGFP1-N1

Catalog No(s). **Amount Lot Number**

631973 20 μl pEF1α-AcGFP1-N1 vector (500 ng/μl) Specified on product label.

pEF1α-AcGFP1-N1 Vector Information




Figure 1. pEF1α-AcGFP1-N1 vector map.

Nhel																
AfeI												Hin	dIII	EcoRI		
1346	ACG	CTA	GCG	CTA	CCG	GAC	TCA	GAT	CTC	GAG	CTC	AAG	CTT	CGA	ATT	CTG

		BamHI														
	AccI SalI			KpnI			XmaI									
				Acc65I			SmaI						Star	t AcG	FP1	
1394	CAG	TCG	ACG	GTA	CCG	CGG	GCC	CGG	GAT	CCA	CCG	GTC	ATG	GTG	AGC	•

Figure 2. pEF1α-AcGFP1-N1 multiple cloning site.

Clontech Laboratories, Inc.

A Takara Bio Company

1290 Terra Bella Avenue, Mountain View, CA 94043, USA

Asia Pacific

U.S. Technical Support: tech@clontech.com

800.662.2566 Late update: July 12, 2011

United States/Canada

Europe Japan +1.650.919.7300+33.(0)1.3904.6880 +81.(0)77.543.6116

Location of Features

- $P_{\rm EF1\alpha}$ (human elongation factor 1 alpha promoter): 12–1346
- MCS (multiple cloning site): 1348–1422
- AcGFP1(human-codon-optimized): 1430–2146
- SV40 polyA signal: 2302–2336
- f1 origin of replication: 2399–2854 (complementary)
- $P_{\text{SV40 e}}$ (SV40 early promoter and enhancer sequences): 3028–3296
- SV40 origin of replication: 3195–3333
- Kan^r/Neo^r (kanamycin/neomycin resistance gene): 3379–4173
- HSV TK polyA signals: 4409–4427
- pUC origin of replication: 4758–5401

NOTICE TO PURCHASER:

Clontech products are to be used for research purposes only. They may not be used for any other purpose, including, but not limited to, use in drugs, in vitro diagnostic purposes, therapeutics, or in humans. Clontech products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products or to provide a service to third parties without prior written approval of Clontech Laboratories, Inc.

Your use of this product is also subject to compliance with the licensing requirements listed below and described on the product's web page at http://www.clontech.com. It is your responsibility to review, understand and adhere to any restrictions imposed by these statements.

Last update: July 12, 2011 Page 2 of 2